Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Risk Communication Panel To Continue Discussion Of Uncertainty Messaging

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA looking for more help from advisory committee on how much information about uncertainty to give as well as how best to communicate it to minority, uneducated groups.

You may also be interested in...

Should FDA Make Patients Care About A Problem If They Don’t Already?

FDA’s Risk Communication Advisory Committee discusses best ways to communicate uncertainty, including how aggressive FDA should be with groups that are not engaged in its messages.

Rx Safety Communication In Face Of Uncertainty, Multiple Risks, To Be Examined By FDA Panel

FDA’s Risk Communication Advisory Committee will delve into research on communicating uncertainty and how individuals perceive risk and seek information when confronted with multiple risks, during a June 29 meeting.

Can't Please Everybody: FDA's "Brief Summary" Redesign May Require Flexibility

Drug Facts Box format scored well in a broad study, but researchers found it may not be the best format for everyone.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts